John Sharrar advises both public and private companies on a broad range of corporate and securities matters, including public and private securities offerings, mergers and acquisitions, securities law compliance, and corporate governance.

John helps clients effectively execute complex business transactions and regularly counsels companies regarding ongoing SEC disclosure obligations. John has represented clients from a broad range of industries, with a focus in the life sciences sector.

Prior to law school, John worked as a legislative correspondent in the U.S. House of Representatives, where he focused on entrepreneurship and small business policy.

Before joining Hogan Lovells, John advised clients on securities and general corporate matters as an associate at a national law firm.

Education and admissions

Education

J.D., Temple University School of Law, magna cum laude, 2015

B.A., University of Pennsylvania, 2009

Bar admissions and qualifications

Pennsylvania

Representative experience

Advised OptiNose on its US$120m offering of common stock.

Represented Sesen Bio, Inc. on its US$30m offering of common stock and warrants.

Represented Arbutus Biopharma Corporation on an at-the-market equity offering led by Jefferies.

Represented Rexahn Pharmaceuticals, Inc. on its US$8.6m offering of common stock and warrants.

Advised publicly traded life sciences company on its acquisition of genetic sequencing startup.

Represented Pareteum Corporation (NASDAQ: TEUM) in its US$104m acquisition of Artilium plc (AIM: ARTA), pursuant to a U.K.-court sanctioned scheme of arrangement.

Loading data